플러스100%마이너스

통합검색
닫기

KMCRIC 챗봇에게

질문하기!

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus.

Authors

Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC, Sivieri K.

Journal

Lipids Health Dis.

Year

2012

Vol (Issue)

11

Page

29.

doi

10.1186/1476-511X-11-29.

PMID

22356933

Url

http://www.ncbi.nlm.nih.gov/pubmed/22356933

MeSH

Administration, Oral
Bifidobacterium
Blood Glucose
Cholesterol/blood
Diabetes Mellitus, Type 2/complications
Diabetes Mellitus, Type 2/therapy*
Double-Blind Method
Female
Humans
Hypercholesterolemia/complications
Hypercholesterolemia/therapy*
Hypertriglyceridemia/complications
Hypertriglyceridemia/therapy*
Hypoglycemic Agents/administration & dosage
Hypoglycemic Agents/therapeutic use*
Hypolipidemic Agents/administration & dosage
Hypolipidemic Agents/therapeutic use*
Lactobacillus acidophilus
Male
Middle Aged
Oligosaccharides/administration & dosage
Oligosaccharides/therapeutic use*
Probiotics/administration & dosage
Probiotics/therapeutic use*
Symbiosis
Treatment Outcome

Keywords

Bifidobacterium bifidum; Fructooligosaccharide; Lactobacillus acidophilus; Symbiotics; Shake

한글 키워드

비피도박테리움 비피둠; 프락토올리고당; 락토바실러스 아시도필루스; 심바이오틱스; 흔들다

KMCRIC summary and commentary

없음

Korean Study

Abstract

BACKGROUND:
The consumption of foods containing probiotic and prebiotic ingredients is growing consistently every year, and in view of the limited number of studies investigating their effect in the elderly.
OBJECTIVE:
The objective of this study was to evaluate the effect of the consumption of a symbiotic shake containing Lactobacillus acidophilus, Bifidobacterium bifidum and fructooligosaccharides on glycemia and cholesterol levels in elderly people.
METHODS:
A randomized, double-blind, placebo-controlled study was conducted on twenty volunteers (ten for placebo group and ten for symbiotic group), aged 50 to 60 years. The criteria for inclusion in the study were: total cholesterol > 200 mg/dL; triglycerides > 200 mg/dL and glycemia > 110 mg/dL. Over a total test period of 30 days, 10 individuals (the symbiotic group) consumed a daily dose of 200 mL of a symbiotic shake containing 10(8) UFC/mL Lactobacillus acidophilus, 10(8) UFC/mL Bifidobacterium bifidum and 2 g oligofructose, while 10 other volunteers (the placebo group) drank daily the same amount of a shake that did not contain any symbiotic bacteria. Blood samples were collected 15 days prior to the start of the experiment and at 10-day intervals after the beginning of the shake intake. The standard lipid profile (total cholesterol, triglycerides and HDL cholesterol) and glycemia, or blood sugar levels, were evaluated by an enzyme colorimetric assay.
RESULTS:
The results of the symbiotic group showed a non-significant reduction (P > 0.05) in total cholesterol and triglycerides, a significant increase (P < 0.05) in HDL cholesterol and a significant reduction (P < 0.05) in fasting glycemia. No significant changes were observed in the placebo group.
CONCLUSION:
The consumption of symbiotic shake resulted in a significant increase in HDL and a significant decrease of glycemia.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT00123456.

국문초록

Language

영어

첨부파일